Twinlab
This article was originally published in The Tan Sheet
Executive Summary
Ephedra-containing products comprised about 20% of third quarter sales, Chairman & CEO Ross Blechman reports during an analysts call Nov. 11. Although he says recent ephedra studies in prominent medical journals are "old news," Blechman notes the firm is posting strong labeling warnings on products and is preparing for contingencies related to changes in federal policy toward the controversial herbal. Twinlab recorded a net loss of $11.1 mil. for the quarter, compared to income of $2.8 mil. in the 1999 period. Additional earnings details come after the company had to file an extension for its 10-Q due to inventory problems (1"The Tan Sheet" Nov. 20, p. 5)
|
Ephedra-containing products comprised about 20% of third quarter sales, Chairman & CEO Ross Blechman reports during an analysts call Nov. 11. Although he says recent ephedra studies in prominent medical journals are "old news," Blechman notes the firm is posting strong labeling warnings on products and is preparing for contingencies related to changes in federal policy toward the controversial herbal. Twinlab recorded a net loss of $11.1 mil. for the quarter, compared to income of $2.8 mil. in the 1999 period. Additional earnings details come after the company had to file an extension for its 10-Q due to inventory problems (1 (Also see "Twinlab Sales Affected By Product Returns, Inventory Reduction" - Pink Sheet, 20 Nov, 2000.)). |